| Identification | Back Directory | [Name]
Butanoic acid, 4-amino-, 2-[4-[3-(2-chloro-10H-phenothiazin-10-yl)propyl]-1-piperazinyl]ethyl ester, methanesulfonate (1:3) | [CAS]
916898-61-8 | [Synonyms]
CYP-1020
BL-1020 Mesylate
Perphenazine GABA ester
Butanoic acid, 4-amino-, 2-[4-[3-(2-chloro-10H-phenothiazin-10-yl)propyl]-1-piperazinyl]ethyl ester, methanesulfonate (1:3) | [Molecular Formula]
C26H37ClN4O5S2 | [MOL File]
916898-61-8.mol | [Molecular Weight]
585.18 |
| Hazard Information | Back Directory | [Description]
BL-1020, also known as CYP-1020; AN-168, a GABA A receptor agonist and dopamine receptor antagonist potentially for the treatment of schizophrenia, BL-1020 is an ester of GABA and perphenazine, and pharmacologically it acts as a D2 antagonist and GABA agonist. It has shown pro-cognitive effects in the trials. In March 2013, it went into the II/III trial phase. It has been introduced by BioLineRx, a biopharmaceutical development company. |
|
|